Monte Rosa Therapeutics, Inc. Common Stock

GLUENASDAQ • USD
8.96 USD
↘ 0.20 (2.17%)🟢LIVE (AS OF 11:53 AM EST)
🟢Market: OPEN

Shares of Monte Rosa Therapeutics, Inc. Common Stock (GLUE) are trading at $8.96. The technical outlook is "Strong Sell" and the fundamental picture shows "Neutral". Key drivers include a concerning Altman Z-Score in the distress zone, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. GLUE is fairly valued relative to its sector peers based on current multiples.

Technical & fundamental data as of Nov 16, 2026.

Open?$9.19
High?$9.30
Low?$8.84
Prev. Close?$9.16
Volume?321.9K
Avg. Volume?1.5M
VWAP?$9.01
Rel. Volume?0.22x
Bid / Ask
Bid?$8.53 × 100
Ask?$8.86 × 200
Spread?$0.33
Midpoint?$8.70
Valuation & Ratios
Market Cap?782.7M
Shares Out?85.5M
Float?73.5M
Float %?86.1%
P/E Ratio?N/A
P/B Ratio?1.58
EPS?-$1.53
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).
Employees
173
Market Cap
800.7M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed
2021-06-24
Address
321 HARRISON AVENUE
BOSTON, MA 02118
Phone: 617-949-2643
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-3/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
40
Z-Score?
23
Momentum?
97
Short Sent.?
30
Piotroski F-Score?4/9Mixed
Altman Z-Score?1.58Distress
Confidence?54%Low
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?28.38%Squeeze Risk
Short Interest?20.9M
Days to Cover?15.7
Free Float73.5M
Avg Daily Volume1.3M
Settlement Date2026-10-30
Financial Health
Current Ratio?10.32Strong
Quick Ratio?10.32Strong
Cash Ratio?0.73Adequate
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
67/100
P/E?
N/A▾
P/B?
Peers
100
S&P
85
1.58CHEAP▾
P/S?
Peers
100
S&P
7
11.13HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-5.2CHEAP▾
EV/Sales?
Peers
100
S&P
10
10.49HIGH▾
Returns & Efficiency
ROE?
S&P
7
-26.4%WEAK▾
ROA?
S&P
3
-18.8%WEAK▾
Cash Flow & Enterprise
FCF?$-174391000
Enterprise Value?$737.5M
Fundamentals ratios updated end of day